These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 21557940)

  • 1. Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cells.
    Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    FEBS Lett; 2011 Jun; 585(12):1884-90. PubMed ID: 21557940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice.
    Abe M; Funakoshi-Tago M; Tago K; Kamishimoto J; Aizu-Yokota E; Sonoda Y; Kasahara T
    Int Immunopharmacol; 2009 Jul; 9(7-8):870-7. PubMed ID: 19327411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
    PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
    Funakoshi-Tago M; Nagata T; Tago K; Tsukada M; Tanaka K; Nakamura S; Mashino T; Kasahara T
    Cell Signal; 2012 Nov; 24(11):2024-34. PubMed ID: 22750290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.
    Liu LZ; Zhou XD; Qian G; Shi X; Fang J; Jiang BH
    Cancer Res; 2007 Jul; 67(13):6325-32. PubMed ID: 17616691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity.
    Zhang Y; Shen X
    Clin Cancer Res; 2007 May; 13(10):2855-64. PubMed ID: 17504983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-resistant cancer cells are sensitive to Aurora kinase A inhibition by alisertib.
    Wang L; Arras J; Katsha A; Hamdan S; Belkhiri A; Ecsedy J; El-Rifai W
    Mol Oncol; 2017 Aug; 11(8):981-995. PubMed ID: 28417568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
    Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
    Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
    Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
    Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line.
    Schenk PW; Boersma AW; Brandsma JA; den Dulk H; Burger H; Stoter G; Brouwer J; Nooter K
    Cancer Res; 2001 Oct; 61(19):6982-6. PubMed ID: 11585720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemical modification on the ability of pyrrolidinium fullerene to induce apoptosis of cells transformed by JAK2 V617F mutant.
    Funakoshi-Tago M; Tsukada M; Watanabe T; Mameda Y; Tago K; Ohe T; Nakamura S; Mashino T; Kasahara T
    Int Immunopharmacol; 2014 May; 20(1):258-63. PubMed ID: 24631513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity.
    Kim M; Yan Y; Kortum RL; Stoeger SM; Sgagias MK; Lee K; Lewis RE; Cowan KH
    Cancer Res; 2005 May; 65(10):3986-92. PubMed ID: 15899786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of Aurora-A kinase promotes tumor cell proliferation and inhibits apoptosis in esophageal squamous cell carcinoma cell line.
    Wang XX; Liu R; Jin SQ; Fan FY; Zhan QM
    Cell Res; 2006 Apr; 16(4):356-66. PubMed ID: 16617331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cell signaling and CDDP resistance].
    Masumoto N; Nakano S
    Gan To Kagaku Ryoho; 1997 Feb; 24(4):424-30. PubMed ID: 9063479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
    Asechi H; Hatano E; Nitta T; Tada M; Iwaisako K; Tamaki N; Nagata H; Narita M; Yanagida A; Ikai I; Uemoto S
    Int J Oncol; 2010 Jul; 37(1):89-96. PubMed ID: 20514400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.